Tempus AI, Inc. $TEM Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Key Points

• Sumitomo Mitsui Trust Group increased its stake in Tempus AI by 1.2%, owning 3,504,823 shares (about 1.97% of the company) valued at roughly $206.96 million at the end of the quarter.
• Significant insider selling occurred: the CFO and CEO sold shares at about $59.05 on Feb. 19, and insiders disposed of 563,841 shares worth $32.26 million over the last quarter, though insiders still own 26.27% of the stock.
• Analysts give Tempus AI a consensus rating of “Moderate Buy” with a $75.92 average target, but recent notes show mixed views and several price-target cuts from firms like BTIG and Morgan Stanley.

Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,504,823 shares of the company's stock after buying an additional 41,728 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 1.97% of Tempus AI worth $206,960,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of TEM. Cranbrook Wealth Management LLC acquired a new position in shares of Tempus AI in the 3rd quarter valued at $25,000. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI in the 3rd quarter valued at $26,000. GAMMA Investing LLC purchased a new stake in shares of Tempus AI in the 3rd quarter valued at $28,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Tempus AI in the 3rd quarter valued at $38,000. Finally, Lodestone Wealth Management LLC purchased a new stake in shares of Tempus AI in the 4th quarter valued at $42,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $42.94 on Monday. The stock's 50-day moving average is $51.10 and its two-hundred day moving average is $66.77. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. Tempus AI, Inc. has a 1-year low of $38.79 and a 1-year high of $104.32. The company has a market cap of $7.68 billion, a price-to-earnings ratio of -30.45 and a beta of 4.90.

Insider Activity at Tempus AI

In other Tempus AI news, CFO James William Rogers sold 10,084 shares of the company's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $595,460.20. Following the sale, the chief financial officer owned 101,166 shares in the company, valued at $5,973,852.30. This represents a 9.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ryan Fukushima sold 9,592 shares of the company's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the sale, the chief executive officer owned 694,354 shares in the company, valued at approximately $41,001,603.70. This trade represents a 1.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 563,841 shares of company stock worth $32,258,311 over the last quarter. 26.27% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

TEM has been the topic of several research analyst reports. BTIG Research cut their price objective on Tempus AI from $105.00 to $90.00 and set a "buy" rating on the stock in a report on Wednesday, February 25th. Mizuho initiated coverage on Tempus AI in a report on Thursday, February 19th. They issued an "outperform" rating and a $100.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of Tempus AI in a report on Wednesday, March 11th. Wall Street Zen downgraded Tempus AI from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Finally, Morgan Stanley cut their price objective on Tempus AI from $85.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, March 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $75.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.